Treatment
Immunoglobulins clinical trials
We’re tracking 79 recruiting studies that include Immunoglobulins, each written for real people, not researchers, below.
Recruiting studies
- NCT07182227RecruitingPhase 1/Phase 2
Gene therapy for IgA nephropathy kidney disease
This trial tests a new gene therapy called PS-002 for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The treatment aims to reduce kidney damage, and this study will help determine if it is safe and effective.
Miami, FloridaAges 18 years+ - NCT07149454Enrolling by invitationPhase 1
Testing a new antibody to prevent tetanus
This trial tests a new medicine made from antibodies that target tetanus toxin. It may help protect people from tetanus without needing a vaccine.
Lanzhou, GansuAges 18–60 - NCT07146906RecruitingPhase 2
Study of zigakibart for IgA nephropathy
This trial tests a new drug called zigakibart for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help reduce protein in the urine and protect kidney function.
Denver, ColoradoAges 18–100 - NCT07094048RecruitingPhase 4
Immunoglobulins for multiple myeloma patients on BCMA T-cell engagers
This trial tests whether giving immunoglobulins (a treatment to boost your immune system) helps multiple myeloma patients who are receiving a BCMA-directed T-cell engager therapy. It aims to see if this can reduce infections and improve outcomes.
Lévis, QuebecAges 18 years+ - NCT07059000RecruitingPhase 3
Study of a drug for adults with chronic ITP
This trial tests an intravenous immunoglobulin (IVIg) treatment for adults who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if this treatment can safely raise your platelet count.
Los Angeles, CaliforniaAges 18–70 - NCT06994845RecruitingPhase 3
Testing iptacopan for children with IgA nephropathy
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
Madera, CaliforniaAges 2–18 - NCT06989541Recruiting
Immunoglobulin for low antibodies after CAR T-cell therapy
This trial tests whether giving immunoglobulin (a treatment that boosts your antibodies) can help people who developed very low antibody levels after CAR T-cell therapy for cancer. It may help prevent infections and improve recovery.
Edmonton, AlbertaAges 18 years+ - NCT06958796RecruitingPhase 4
CMV immunoglobulin to prevent disease after transplant
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Boston, MassachusettsAges 18–75 - NCT06925360RecruitingPhase 2
IVIG for lung disease in premature babies
This trial tests if intravenous immunoglobulin (IVIG) can help prevent or treat bronchopulmonary dysplasia (BPD), a lung condition in premature babies. It is for very preterm infants born between 25 and 29 weeks who show early signs of BPD and are enrolled in the first day of life.
Shanghai, Shanghai MunicipalityAges Up to 2 months - NCT06895538RecruitingPhase 2/Phase 3
Comparing two immune treatments for stem cell transplant patients
This trial compares two drugs, ATLG and ATG, to see which one helps rebuild the immune system better after a stem cell transplant for blood cancer. It aims to improve recovery and reduce complications.
BeijingAges 18 years+ - NCT06858319RecruitingPhase 3
Long-term study of zigakibart for IgA nephropathy
This study is for people with IgA nephropathy who completed a previous zigakibart study. It tests whether continuing treatment with zigakibart (given as a shot every two weeks) is safe and helpful over a longer period.
Denver, ColoradoAges 18–100 - NCT06834035RecruitingPhase 1/Phase 2
IV IgG for collagen VII antibodies in dystrophic epidermolysis bullosa
This trial tests if intravenous immunoglobulin (IV IgG) can help people with a form of epidermolysis bullosa who have antibodies against collagen VII. It may reduce blistering and improve wound healing.
Redwood City, CaliforniaAges 6 years+ - NCT06797518RecruitingPhase 2
Testing iptacopan for IgA nephropathy kidney changes
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
Birmingham, AlabamaAges 18–99 - NCT06768489RecruitingPhase 1
Combination therapy for multiple myeloma and related conditions
This trial tests a new drug combined with other medicines for people with multiple myeloma, a related condition called AL amyloidosis, or high-risk smoldering multiple myeloma. It aims to see if the combination is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06676579RecruitingPhase 2
Avacopan for active IgA kidney disease with crescents
This trial tests if avacopan, a targeted anti-inflammatory drug, can safely treat a severe form of IgA nephropathy (IgAN) where small crescents form in the kidney filters. It may help reduce protein leakage and preserve kidney function.
Jacksonville, FloridaAges 18 years+ - NCT06599697RecruitingPhase 2
IVIG for anti-HMGCR muscle disease
This trial tests if IVIG (intravenous immunoglobulin, a donated blood product that helps the immune system) can improve muscle strength and reduce damage in people with anti-HMGCR immune-mediated necrotizing myopathy (a rare muscle disease where the immune system attacks muscle cells). It may help you if your muscle weakness is not too severe and you haven't tried IVIG before.
Birmingham, AlabamaAges 16 years+ - NCT06573723Recruiting
Rare disease registry at Hospital Italiano
This study collects information from patients with certain rare diseases to better understand them. If you have one of these conditions and receive care at Hospital Italiano de Buenos Aires, you may be able to join.
Buenos Aires, Buenos AiresAges Any age - NCT06466135RecruitingPhase 2
Study of WAL0921 for glomerular kidney diseases
This study tests a new drug called WAL0921 for people with certain types of kidney disease. The goal is to see if it can help protect kidney function.
Los Angeles, CaliforniaAges 18–75 - NCT06350630RecruitingPhase 2
Hydroxychloroquine for IgA nephropathy
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
Clermont-FerrandAges 18 years+ - NCT06290141RecruitingPhase 3
Testing riliprubart vs. standard IVIg for CIDP
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
Homewood, AlabamaAges 18 years+ - NCT05689463Recruiting
Testing antibodies in itching after immune therapy
This study checks blood antibodies (BP180 and BP230) in people who develop long-lasting itching after starting immune therapy for cancer. It may help doctors understand why the itching happens and how it relates to autoimmune skin conditions.
RouenAges 18 years+ - NCT05584631RecruitingPhase 1
Switching IVIG to weekly SCIG for CIDP treatment
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
New Brunswick, New JerseyAges 18–65 - NCT05350774Enrolling by invitationPhase 2
IV immunotherapy for lingering neurologic effects after COVID-19
This Phase 2 trial tests whether intravenous immunotherapy (IVIG) can improve ongoing neurologic symptoms after a mild-to-moderate COVID-19 illness. It targets people with persistent symptoms such as brain fog, fatigue, trouble thinking, dizziness when standing, and balance or other neurologic problems.
Bethesda, MarylandAges 18–100 - NCT05325008RecruitingPhase 3
IVIG treatment for BK virus after kidney transplant
This Phase 3 trial tests IVIG (an antibody medicine given through a vein) to treat BK virus infection after kidney or pancreas-kidney transplant. It may help lower the BK virus in the blood and protect the transplanted kidney.
Canberra, Australian Capital TerritoryAges 2 years+
Common questions
- Are there clinical trials studying Immunoglobulins?
- Yes. Clin2 currently lists 79 recruiting studies that include Immunoglobulins, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Immunoglobulins trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Immunoglobulins an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Immunoglobulins or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.